Yuval Pemper - Innovid Corp Chief Officer
CTVDelisted Stock | USD 3.14 0.00 0.00% |
Insider
Yuval Pemper is Chief Officer of Innovid Corp
Age | 54 |
Phone | 212 966 7555 |
Web | https://www.innovid.com |
Innovid Corp Management Efficiency
The company has Return on Asset of (0.0257) % which means that on every $100 spent on assets, it lost $0.0257. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0702) %, meaning that it generated no profit with money invested by stockholders. Innovid Corp's management efficiency ratios could be used to measure how well Innovid Corp manages its routine affairs as well as how well it operates its assets and liabilities.Innovid Corp has 21.83 M in debt with debt to equity (D/E) ratio of 0.09, which may show that the company is not taking advantage of profits from borrowing. Innovid Corp has a current ratio of 2.64, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Innovid to invest in growth at high rates of return.
Similar Executives
Showing other executives | INSIDER Age | ||
MS MBA | ADC Therapeutics SA | 52 | |
Susan Romanus | ADC Therapeutics SA | 59 | |
Ye Li | CTS Corporation | 53 | |
Anshuman Mehrotra | Belden Inc | 53 | |
Jacques Theurillat | ADC Therapeutics SA | 62 | |
Joseph Camardo | ADC Therapeutics SA | 71 | |
Kimberly Pope | ADC Therapeutics SA | 58 | |
Stephen Evansfreke | ADC Therapeutics SA | 68 | |
Lajuana Johnson | Comtech Telecommunications Corp | N/A | |
Jennie Reilly | Comtech Telecommunications Corp | N/A | |
Scott DAngelo | CTS Corporation | 54 | |
Mitchell Walorski | CTS Corporation | N/A | |
Robert Schmidt | ADC Therapeutics SA | 43 | |
Dr DPHIL | ADC Therapeutics SA | 65 | |
Leo Kulmaczewski | Belden Inc | 58 | |
Richard Onyett | ADC Therapeutics SA | 73 | |
Thomas White | CTS Corporation | 38 | |
Ashish Chand | Belden Inc | 50 | |
Lisa Skelton | ADC Therapeutics SA | 53 | |
Gregory McCray | Belden Inc | 57 | |
Stephane Henchoz | ADC Therapeutics SA | N/A |
Management Performance
Return On Equity | -0.0702 | |||
Return On Asset | -0.0257 |
Innovid Corp Leadership Team
Elected by the shareholders, the Innovid Corp's board of directors comprises two types of representatives: Innovid Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovid. The board's role is to monitor Innovid Corp's management team and ensure that shareholders' interests are well served. Innovid Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovid Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tanya AndreevKaspin, Executive Officer | ||
Tim Braz, VP Sales | ||
Stephanie Geno, Chief Officer | ||
Stephen Cook, General Counsel | ||
Ken Markus, Chief Officer | ||
John Williams, Head Relations | ||
Pr Netter, CEO CoFounder | ||
Michal Livny, Executive Resources | ||
Alex Rowe, Senior Sales | ||
Anthony Callini, Chief Officer | ||
Dani Cushion, Chief Officer | ||
David Helmreich, Chief Officer | ||
Jeff Austin, Senior Operations | ||
Kenneth Markus, Chief Officer | ||
Liel Golan, Executive Operations | ||
Yuval Pemper, Chief Officer | ||
Sarah Ripmaster, Senior Accounts | ||
Tal Chalozin, CoFounder CTO | ||
Arik Shahar, VP Measurement | ||
Guy Kuperman, Chief Officer |
Innovid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innovid Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0702 | |||
Return On Asset | -0.0257 | |||
Profit Margin | (0.09) % | |||
Operating Margin | (0.04) % | |||
Current Valuation | 450.54 M | |||
Shares Outstanding | 150.92 M | |||
Shares Owned By Insiders | 7.27 % | |||
Shares Owned By Institutions | 55.65 % | |||
Number Of Shares Shorted | 3.46 M | |||
Price To Earning | 23.87 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Innovid Stock
If you are still planning to invest in Innovid Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Innovid Corp's history and understand the potential risks before investing.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |